Rigel Pharmaceuticals Inc RIGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rigel to Present at the Jefferies Global Healthcare Conference
-
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
-
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
-
Arvinas, Pfizer Tap Rigel Pharmaceuticals to Bring Veppanu to Market
-
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
-
Rigel Reports First Quarter 2026 Financial Results
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $30.08
- Day Range
- $30.13–31.07
- 52-Week Range
- $18.14–52.24
- Bid/Ask
- $27.92 / $31.80
- Shares Outstanding
- 18.50M
- Market Cap
- $568.38M
- Volume/Avg
- 238,825 / 375,439
Key Statistics
- Price/Earnings (Normalized)
- 4.76
- Price/Sales
- 1.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 174
- Website
- https://www.rigel.com
Valuation
|
Metric
|
RIGL
|
|---|---|
Price/Earnings (Normalized) | 4.76 |
Price/Book Value | 1.39 |
Price/Sales | 1.93 |
Price/Cash Flow | 6.08 |
Price/Earnings
RIGL
Financial Strength
|
Metric
|
RIGL
|
|---|---|
Quick Ratio | 2.20 |
Current Ratio | 2.62 |
Interest Coverage | 18.05 |
Quick Ratio
RIGL
Profitability
|
Metric
|
RIGL
|
|---|---|
Return on Assets (Normalized) | 113.90% |
Return on Equity (Normalized) | 185.43% |
Return on Invested Capital (Normalized) | 145.74% |
Return on Assets
RIGL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Dyhkmsfw | Qycbsm | $112B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tzwmyfsh | Tfpjyy | $64B | |||
| argenx SE ADR
ARGX
| Lwmlnsjr | Wps | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ldlzfwxb | Vzhhbpm | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Vsrgjkdl | Mwvdky | $24B | |||
| BioNTech SE ADR
BNTX
| Jjjjfkyhn | Bhyf | $22B | |||
| Incyte Corp
INCY
| Klnjpth | Jygj | $20B | |||
| Moderna Inc
MRNA
| Hvfjyplpj | Cbk | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Qqxzxgjs | Myq | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Hkcwhnfnc | Jrtt | $13B |
United States